156 related articles for article (PubMed ID: 16410744)
1. Genetic alterations in primary glioblastomas in Japan.
Fukushima T; Favereaux A; Huang H; Shimizu T; Yonekawa Y; Nakazato Y; Ohagki H
J Neuropathol Exp Neurol; 2006 Jan; 65(1):12-8. PubMed ID: 16410744
[TBL] [Abstract][Full Text] [Related]
2. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
3. Genetic pathways to glioblastoma: a population-based study.
Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
5. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent prognostic effects of genetic alterations in glioblastoma.
Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
[TBL] [Abstract][Full Text] [Related]
7. Glioblastomas with an oligodendroglial component: a pathological and molecular study.
He J; Mokhtari K; Sanson M; Marie Y; Kujas M; Huguet S; Leuraud P; Capelle L; Delattre JY; Poirier J; Hoang-Xuan K
J Neuropathol Exp Neurol; 2001 Sep; 60(9):863-71. PubMed ID: 11556543
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
[TBL] [Abstract][Full Text] [Related]
9. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
10. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
11. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
Hegi ME; zur Hausen A; Rüedi D; Malin G; Kleihues P
Int J Cancer; 1997 Sep; 73(1):57-63. PubMed ID: 9334810
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.
Fujisawa H; Reis RM; Nakamura M; Colella S; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 2000 Jan; 80(1):65-72. PubMed ID: 10653004
[TBL] [Abstract][Full Text] [Related]
13. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
14. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.
Martinez R; Schackert HK; von Kannen S; Lichter P; Joos S; Schackert G
Brain Pathol; 2003 Oct; 13(4):598-607. PubMed ID: 14655763
[TBL] [Abstract][Full Text] [Related]
15. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
16. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
Schmidt EE; Ichimura K; Goike HM; Moshref A; Liu L; Collins VP
J Neuropathol Exp Neurol; 1999 Nov; 58(11):1170-83. PubMed ID: 10560660
[TBL] [Abstract][Full Text] [Related]
17. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
Liu W; James CD; Frederick L; Alderete BE; Jenkins RB
Cancer Res; 1997 Dec; 57(23):5254-7. PubMed ID: 9393744
[TBL] [Abstract][Full Text] [Related]
18. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
[TBL] [Abstract][Full Text] [Related]
19. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
20. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
